Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 12;9(3):803–821. doi: 10.1007/s40744-022-00443-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 3 — Prevalence of skin disease by PASI, where reported. Note: Unless stated otherwise, shapes with hatching refer to patients assessed by DAPSA, not cDAPSA. Asterisk indicates that data were inversed for ease of comparison (e.g. percentage of patients with PASI ≤ 1 has been transformed into percentage of patients with PASI > 1). [a] VLDA group: in a separate subgroup analysis of n = 15, 12 (80.0%) patients had PASI 0–0.3, 2 (13.3%) patients had PASI 0.4–0.6 and 1 (6.7%) patient had PASI 0.7–1; DAPSA REM group: in a separate subgroup analysis of n = 18, 11 (61.1%) patients had PASI 0–0.3, 2 (11.1%) patients had PASI 0.4–0.6 and 5 (27.7%) patients had PASI > 1. [b] cDAPSA REM: in a separate subgroup analysis of n = 22, 14 (63.6%) patients had PASI 0–0.3, 2 (9.0%) patients had PASI 0.4–0.6, 1 (4.5%) patient had PASI 0.7–1 and 5 (22.7%) patients had PASI > 1. [c] p = 0.002 VLDA + MDA vs. non-MDA. PASI Psoriasis Area and Severity Index